ChemExpress
Established in 2006, Shanghai Haoyuan ChemExpress Co., Ltd. is headquartered in Shanghai, China, with a major overseas branch—MedChemExpress LLC—located in New Jersey, USA. Today, ChemExpress operates five R&D centers and five manufacturing facilities, supporting global pharmaceutical and biotech partners across the full drug development lifecycle
ChemExpress provides end-to-end CRO and CDMO services spanning small molecules, biologics, and new modalities, including ADCs/XDCs, peptides, and PROTACs. Our comprehensive platform covers the research, development, and manufacturing of regulatory starting materials, novel building blocks & intermediates, reference standards, drug substances (DS) and drug products (DP), including solid, semi-solid, liquid, and lyophilized biologics. We support programs from early discovery, process optimization, GMP manufacturing, to commercialization.
Leadership in ADC/CDMO Development
ChemExpress has established a highly specialized platform dedicated to Antibody–Drug Conjugates (ADCs), offering integrated research, process development, and GMP manufacturing services. Our ADC expertise spans the entire value chain: Antibodies, Payloads, Linkers, Payload–linker synthesis, Bioconjugation, ADC drug substance & drug product manufacturing. We support global clients from early R&D through clinical supply and commercial readiness
ChemExpress maintains one of the industry’s most complete payload–linker libraries: 80+ payloads, 400+ linkers, combinable payload–linker modules in stock, 15 US FDA-DMF-filed payloads & related intermediates, including MMAE, Vc-MMAE, Exatecan, and Eribulin. This broad and ready-to-use inventory enables rapid project initiation and efficient CMC development.
In the past year alone, ChemExpress has completed 160+ ADC-related projects, supported 5 projects entering BLA submission stages, served 990+ biopharma clients worldwide and built a team of 500+ experienced scientists & engineers. Our CDMO services include custom synthesis (FFS/FTE), process development, scale-up (non-GMP & GMP), process validation, CMC strategy, DMF submissions, and IND filing support.
Our end-to-end ADC drug substance and drug product platform supports multiple conjugation technologies, including: non-specific (cysteine, lysine) and site-specific (ThioMAb, bridged cysteine, enzymatic ligation, N-glycan remodeling). We manufacture diverse conjugate modalities: ADCs, PDCs, RDCs, DACs, ApDCs, and AOCs.
ChemExpress maintains strong R&D, QA/QC, and CMC teams, with multiple HPAPI production lines delivering GMP payloads for ADC programs approaching BLA submissions in the U.S., Europe, and China. Our mission is to be the CDMO partner of choice, delivering high-quality products, regulatory-compliant manufacturing, and flexible, cost-effective solutions tailored to the needs of global drug developers.
